Pfizer stock has dropped to levels that income investors rarely see from a Big Pharma name. Shares now trade near $26, pushing the forward dividend yield above 6.4 percent. That is well above the stock’s five-year average yield of 4.5 percent.
Pfizer’s dividend history and current payout
Pfizer has raised its dividend for 17 consecutive years, a record that commands respect from conservative investors. The current annual dividend stands at $1.72 per share. At a share price near $26.45, the yield reaches approximately 6.4 to 6.6 percent depending on the exact entry point.
Management has reiterated its commitment to the dividend despite a challenging post-COVID revenue environment. The company did not raise the payout with its first-quarter 2026 dividend, ending a streak of annual hikes that began in 2011. That pause is worth watching closely.
| Metric | Value |
|---|---|
| Share Price (approx.) | $26.45 |
| Annual Dividend | $1.72 |
| Forward Yield | ~6.4% – 6.6% |
| 5-Year Average Yield | ~4.5% |
| Consecutive Years of Increases | 17 |
| Last Increase | Q1 2026 (maintained, not raised) |
Why the yield has climbed so high
A dividend yield rises for one of two reasons: the company raises the payout, or the share price falls. In Pfizer’s case, it is almost entirely the latter. Revenue has declined sharply since the peak of COVID vaccine and treatment sales. The market has punished the stock while the dividend has remained steady.
For income investors, this creates a dilemma. A 6.4 percent yield from a pharmaceutical giant looks attractive on paper. But a yield driven by price decline rather than payout growth can signal underlying business stress. If earnings and free cash flow continue to fall, the dividend may eventually face pressure.
The pipeline and revenue outlook
Pfizer’s pipeline remains one of the deepest in the industry. Oncology and obesity drug candidates are in late-stage trials, including the oral GLP-1 compound danuglipron that could compete in the weight-loss market. Seagen, acquired for $43 billion in 2023, is contributing cancer therapy revenue that helps offset COVID declines.
Analysts at Morningstar expect Pfizer to return to modest revenue growth by 2027. The consensus forecast calls for approximately $64 billion in 2026 revenue, down from $58.5 billion in 2025 but stabilizing. Free cash flow is projected at roughly $12 to $14 billion annually, which currently covers the dividend with some margin.
Risks income investors should weigh
Pfizer’s pipeline remains robust, with oncology and obesity drug candidates in late-stage trials. However, drug development is expensive and uncertain. The company must replace billions in lost COVID revenue before it can comfortably grow the dividend again.
Debt levels have increased as Pfizer pursued large acquisitions. The balance sheet now carries over $60 billion in long-term debt. Leverage can restrict management’s flexibility during downturns. Conservative investors should monitor the payout ratio and free cash flow coverage each quarter. If the company starts borrowing to fund the dividend, that is a red flag.
Patent cliffs are another concern. Several of Pfizer’s largest non-COVID drugs face generic competition in the late 2020s. The company must launch new blockbusters to replace that revenue. The GLP-1 program is promising but faces fierce competition from Novo Nordisk and Eli Lilly.
What conservative investors should consider
Pfizer at these prices offers a rare yield among blue-chip healthcare names. For a retiree seeking current income, the 6.4 percent yield may justify a modest position. We recommend treating it as a speculative-income holding rather than a core dividend aristocrat until the payout growth resumes.
Diversification matters. No single stock should dominate a retirement income portfolio. Pair a higher-yield name like Pfizer with more stable dividend growers such as Johnson & Johnson or Procter & Gamble to balance current income against long-term reliability.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week. AlphaBetaStock’s free newsletter covers dividend stocks, defensive sectors, and portfolio moves that matter for conservative investors.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
